MedTech Innovator Asia Pacific’s Post

The #biotech industry is driven by innovative startups and collaborations between academia and industry. #UCBerkeley's Health Innovation Accelerator brings together eight promising #biotechstartups from Taiwan and the US. As these teams tackle global health challenges, from vertigo diagnosis to cancer treatment, they're developing groundbreaking solutions while building cross-cultural partnerships. It's exciting to see how programs like this provide a platform for the mentorship, idea sharing, and progress that could shape the future of the biomedical industry! https://loom.ly/HU6tg5o

In a month, two of our Project Leads, Greta Preatoni from MYNERVA and Waldemar Hoffmann from Liver4Life (aka Apersys AG) will head to Boston as part of Venturelab's Venture Leaders Medtech 2024 💫 During the one-week roadshow, the 10 Venture Leaders will meet investors in the USA and engage with executives and experts in the #Medtech industry. Excited to see how this week will transpire 😀 More info about the other Venture Leaders below 👇 #VLeadersMedtech #SwissStartups #MedtechInnovation #InnovationInHealth #SwitzerlandInnovation #FutureOfHealthcare

Venture Kick startup Lymphatica Medtech closes EUR 17.9 million funding round to drive Innovation in Lymphedema Treatment. Congratulations to team of founders Marco Pisano (CEO) and Valentina Triacca (CCO) with their great team! https://lnkd.in/g3vxb34i About: Lymphatica, a medical device company, has raised EUR 17.9 million in Series B funding to accelerate the development and validation of LymphoDrain, the first implantable system for treating chronic lymphedema. Lymphedema, a common side effect of cancer therapies, causes limb swelling, pain, and recurrent infections, impacting over 10 million people in Europe and the U.S. This investment will advance Lymphatica's breakthrough technology, which aims to locally replace the lymphatic drainage function, offering unprecedented benefits to patients and healthcare professionals, and improving the lives of millions worldwide. #VentureKick #MedTech #SwissStartups 

Multiomics diagnostic startup Pleno Inc. has raised $25M in a series B funding round led by Deerfield Management, Foresite Capital, and Medical Excellence Capital, LLC. The funds will support the commercial launch of Pleno's Hypercoding technology, aimed at revolutionizing multiomics analysis for clinical applications. Conor Hale | Fierce Biotech https://lnkd.in/g_CiTsCF #HealthTech

1) "India is doing to global software development capacity what China did to global manufacturing capacity - taking it!" 2) "Lung cancer is worth finding early because we can actually do something about it - that was never true before." Congratulations to Samir Shah, MD, MMM FACR and the Qure.ai team. This is an important milestone and a very significant fundraising round. Amazing. Here are some business observations - all my own and, of course, may be wrong: * India today has a "software mismatch" challenge - it is very difficult to commercialize software in India at effective price points, but very easy to develop unbelievably good software at very low price points. I could argue that the best engineering schools in the world today are in India. * As a result, like other India-based companies, Qure.ai has to commercialize in the very expensive rest of world, hence the need for relatively big fundraising rounds despite the very low development costs. * With respect to the specific product, Qure.ai is taking a big bet - and a smart one. Lung cancer screening is likely to continue to grow in importance but continue to struggle with reimbursement. Using an AI screening tool like Qure.ai, could change that value equation for health systems and result in better cancer detection rates. * With the advent of immunotherapy and its progeny, lung cancer is becoming a manageable disease - it is worth finding as fast as we can because we can increasingly stop it in its tracks. That was never true before. * Many things have to go right for Qure.ai to find its way to the billion dollar outcome, but you can see the outline of the path.

Founded in 2023 by Fanny Jaulin, PhD as a spinoff from the Gustave Roussy Institute, Orakl Oncology combines data and biology to transform cancer drug discovery. Tackling the limitations of traditional clinical trials, Orakl uses AI, patient-specific data (40 variables per patient), and organoids—mini organ models—to create hybrid patient avatars for more accurate drug testing. The startup focuses on colorectal and pancreatic cancers, offering two innovative tools: O-Predict (forecasts patient responses) and O-Validate (validates drug candidates). With €15 million in funding from Singular and Bpifrance, Orakl aims to unblock precision medicine and bring more life-saving treatments to patients. #Startups #Entrepreneurship #Innovation #DigitalMarketing #TechTrends  #AI #VentureCapital #Ecommerce #Leadership #BusinessGrowth Discover the latest success story at The Founders! 🚀 Dive into inspiring startup journeys, tips, and insights. Don't miss out – subscribe now and support the innovators shaping our future! 🌟 www.thefounders.news If you spot any inaccuracies, please let us know so we can correct them. Your feedback helps us improve. Thanks! 

🎉 Exciting News from 52North: $6M Funding Round Closed! 🌍💡 British point-of-care testing innovator 52North has secured $6M in funding, co-led by prominent healthcare venture funds from the US and UK: 🔹 KHP Ventures (King’s Health Partners, London) 🔹 Cedars-Sinai Intellectual Property (Los Angeles) Other backers include: ✨ OKG Capital ✨ Cambridge Enterprise Ventures ✨ Cancer Research Horizons ✨ Macmillan Cancer Support ✨ Angels like Roland Diggelmann (former Roche Diagnostics CEO) 💡 What’s Next? The funds will accelerate the commercialisation of 52North’s Neutrocheck, a breakthrough point-of-care device designed to help cancer patients monitor neutropenia risk. Additionally, it will support the development of: -Aster Platform for remote cell monitoring -Acorn Platform, an AI-driven solution for acute oncology care As CEO Umaima Malik Ahmad stated: “With support from UK and US healthcare leaders, we can expand our product pipeline and reshape urgent care pathways for patients worldwide.” 🌟 #HealthcareInnovation #PointOfCareTesting #OncologyCare #AI #MedicalDevices #FundingNews

Securing funding for medtech, biotech, and digital health start-ups is no small feat. With challenges like high capital requirements, regulatory hurdles, and scalability demands, many struggle to attract investment. Yet, there are numerous examples of start-ups who have defied the odds, showing what’s possible with the right support. 🌟 Pan Cancer T raised €4.25M to advance their groundbreaking TCR-T cell therapy for solid cancers like triple-negative breast cancer. With EIT Health's Catapult programme, they honed their strategy, secured a new investor, and now offer fresh hope for patients. 🌟 Neuroventis (Helpilepsy & MigraineManager), a digital health pioneer addressing gaps in epilepsy and headache care, was acquired by Cascador Health, gaining the resources needed to scale and expand. EIT Health’s early support gave them access to top epilepsy hospitals and pharmaceutical partners, paving the way for their success. These stories highlight the transformative power of innovation and collaboration in healthcare! Learn more about their success and that of MOWOOT and WIVI vision: https://lnkd.in/eBgQ_qNN Rachel Abbott, Roland Kozlowski, Ludovic Ampe, EIT - European Institute of Innovation and Technology, EIT Health #HealthcareInnovation #StartUpFunding #MedTech #BioTech #DigitalHealth

📢 Calling all California-based life sciences startups! California Life Sciences (CLS) is thrilled to announce that we are now accepting pitch applications for our exclusive Investor Partnering Forum, taking place just before the highly anticipated Innovation Showcase. This is a unique opportunity for emerging startups to connect with a curated group of investors, each investor selects up to six companies for one-on-one, 20-minute in-person meetings. Confirmed Investors: AbbVie Ventures, Astellas Pharma Venture Management, Boehringer Ingelheim Venture Fund, Chiesi Global Rare Diseases, Civilization Ventures, Remiges Ventures, Inc., Servier Pharmaceuticals, and Xontogeny. At CLS, we are dedicated to advancing the innovation ecosystem in California, fostering growth, and empowering startups in the life sciences sector. If you're ready to accelerate your journey and connect with key investors, apply today! 🔗Learn more & apply: https://bit.ly/4e2sQcR #Innovation #CaliforniaLifeSciences #partneringforum #pitchyourstartup

Mumbai-based AI diagnostics startup Qure.ai has secured $65 million in a Series D funding round led by Lightspeed Venture Partners and 360 ONE Asset Management. The funds will fuel Qure.AI’s global expansion, including in the US, enhance its AI models, and support strategic acquisitions. The company’s AI-powered solutions, used across 3,000 imaging sites in over 90 countries, outperform human radiologists in diagnosing diseases like tuberculosis, lung cancer, and stroke. Qure.AI’s products are cleared by regulators in the US and EU, underscoring its global impact. #QureAI #AIHealthcare #SeriesDFunding #LightspeedVenture #DiagnosticsInnovation #AIinMedicine #GlobalExpansion #HealthTech #MedicalAI #Radiology #HealthcareInnovation #IndiaStartups #ArtificialIntelligence #MedicalImaging #TechFunding #HealthTechRevolution